Sp717
Q&A
Date
May 8, 2023
Explore related products in the following collection:
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
THE PATIENT WITH PSC AND A RELEVANT STRICTURE: EVALUATION FOR EXTRA-HEPATIC CHOLANGIOCARCINOMA
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…
THE PATIENT WITH PBC AND PERSISTENTLY ELEVATED LIVER TESTS DESPITE UDCA
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…
TREATMENT OF THE PATIENT WITH EARLY PSC: UDCA, ORAL VANCOMYCIN, OR NEITHER
Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…